| Date | Title | Description |
| 06.05.2024 | Exagen Announces Campaign for Lupus Awareness Month | CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patie... |
| 08.03.2024 | Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum | - |
| 07.03.2024 | Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 | - |
| 02.01.2024 | Health | A new test could save arthritis patients time, money and pain. But will it be used? | Arthur Allen | KFF Health News (TNS)
SAN DIEGO — Erinn Maury knew Remicade wasn’t the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte’s swollen, painful joints ... |
| 13.11.2023 | Exagen Inc. Reports Strong Third Quarter 2023 Results | SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. |
| 07.08.2023 | Exagen Inc. Reports Strong Second Quarter 2023 Results | SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. |
| 24.07.2023 | Exagen Inc. Appoints Paul Kim to Board of Directors | SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 202... |
| 15.05.2023 | Exagen Inc. Reports First Quarter 2023 Results | Record Physician Demand for AVISE® CTD |
| 20.03.2023 | Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results | Record AVISE® CTD Volume in 2022 |
| 27.09.2022 | ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health | NORTHBROOK, Ill., Sept. 27, 2022 (GLOBE NEWSWIRE) -- ADM Diagnostics, Inc. (ADMdx) has been awarded a two-year $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Aging (NIA) to develop a d... |
| 26.08.2022 | Octopus rolls out €220 million to drive green power generation, backs Exagen to build largest battery in UK | British renewable energy group specialising in sustainable energy, Octopus Energy Group has unveiled a €220 million fund to drive new green power generation to reduce Europe’s gas reliance. Dubbed the Octopus Energy Development Partnership ... |
| 04.08.2022 | Exagen Inc. Reports Second Quarter 2022 Results | Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters |
| 09.01.2022 | Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection | SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license... |
| 10.11.2021 | Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering | ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage,... |
| 10.11.2021 | Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering | ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage,... |
| 25.10.2021 | Exagen Inc :. Announces $27.2 Million Debt Refinancing | SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an aff... |
| 15.06.2021 | SQI DIAGNOSTICS INC.
SQI Diagnostics Inc. : Announces $3.9 Million Funding via Warrant Exercise by Insiders | TORONTO, June 15, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for ... |
| 15.06.2021 | SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders | |
| 16.11.2020 | Exagen and GSK Partner for Fourth Straight Year | Continued collaboration drives greater awareness of challenges facing lupus diagnosis and management |
| 12.10.2020 | New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors | Findings support the clinical need for an improved SLE diagnostic test |
| 29.09.2020 | Exagen Inc. Announces Agreement with Provider Network of America | Expanding Access for AVISE® Tests to 8 Million Members |
| 23.09.2020 | Exagen Appoints Wendy Johnson to Board of Directors | Additional independent board member will also serve on Audit Committee |
| 28.07.2020 | Exagen Inc. Reports Second Quarter 2020 Results | Testing experiencing monthly sequential improvement; record gross margins of 63% |
| 10.12.2019 | National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board | Members include Dr. Arthur Weinstein, Dr. Joel Kremer, Dr. Anca Askanase, Dr. Andrew Concoff, Dr. Maureen McMahon, and Dr. Vasileios Kyttaris |
| 22.11.2019 | Exagen Extends Agreement with GSK for a Third Year | Continued collaboration to drive greater awareness about challenges facing lupus diagnosis and management |
| 19.08.2019 | Exagen and the University of Washington Collaborate on Lupus and Rheumatoid Arthritis Research | Focus on the development of more effective tools to diagnose, prognose and monitor these diseases. |
| 30.07.2019 | Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson | Exagen reinforces board with extensive experience across the laboratory testing and healthcare sectors |
| 02.01.2019 | Exagen Enters Second-Year Agreement with GSK | Collaboration to drive greater awareness about challenges facing lupus diagnosis and management |
| 11.09.2017 | Exagen Diagnostics Receives Up To $25M in Debt Financing | Exagen Diagnostics Inc., a Vista, CA- and Albuquerque, NM-based commercial stage specialty diagnostic company, received up to $25m in debt financing.
An affiliate of Innovatus Capital Partners, LLC, provided the term loans.
The company inte... |
| 11.09.2012 |
Exagen Diagnostics Finds $5.3M
| Exagen Diagnostics, a venture-backed developer of molecular diagnostics testing which operates its main laboratory in Vista, California, said it has raised $5.3M. The funding was led by Tullis Health Invesotrs, and also included Sun Mountai... |
| 11.09.2012 | Exagen Diagnostics Raises $5.3M in Equity Funding | Exagen Diagnostics, a Vista, Calif.-based commercial-stage specialty diagnostic company, has raised $5.3m in equity funding.
The round was led by Tullis Health Investors, with participation from Sun Mountain Capital, Cottonwood Technology F... |
